We use cookies on our websites to ensure the proper functioning of the website and to help provide the best user experience. By continuing to use our site, you agree to the use of cookies. Learn more about cookies.

en
- fi
Orion Group
Menu

Building well-being

Research for patient well-being
Living with a diagnosis

Other websites

Wehale.life

Orion Group

Orion's centenary begins
Orion's century
About Orion
Products and services
Partnering and licensing
Investors
Media
Corporate Governance
Sustainability
Contact us

Other websites

Fermion

Careers at Orion

Open vacancies
Working at Orion
Students
Career stories

Research

Orion R&D
Research areas
R&D pipeline
Scientific publications

Health Professionals

Simdax.com
Dexdor.eu
Easyhaler.eu
Intensetimes.eu

Building well-being Building well-being

Research for patient well-being

Living with a diagnosis

Asthma

ALS

Prostate cancer

Breast cancer

Parkinson's disease

Alzheimer's disease

Orion Group Orion Group

Orion's century

1910s

A superstar of Finnish chemistry

It all began with Albin and woodfern

Orion’s milestones in the 1910s

1920s

A tireless promoter of children’s health

One big family

Orion’s milestones in the 1920s

1930s

Finnishness as an advertising asset

PR in the 1930s: Welcome to the Vallila plant!

Orion’s milestones in the 1930s

1940s

A miracle drug amidst the war

Orion relocated

Orion’s milestones in the 1940s

1950s

A legendary school for laboratory assistants

Finns’ favourite ointments

Orion’s milestones in the 1950s

1960s

The man behind the research

An idyllic estate

Orion’s milestones in the 1960s

1970s

How can I help you?

International horizons: rapid tests and Finnishness

Orion’s milestones in the 1970s

1980s

New address: Orionintie 1

“For manly pain” – from drugs to brands

Orion’s milestones in the 1980s

1990s

Joining forces with a competitor

An inhaler that helps asthmatics and the atmosphere

Orion’s milestones in the 1990s

2000s

The long road to market

The last hope for a heart patient

Orion’s milestones in the 2000s

2010s

Pink light to promote girls’ rights

From a mobile phone factory to a pharmaceutical plant

Orion’s milestone in the 2010s

About Orion

Management

Board of Directors

Executive management board

Orion values

Mission and strategy

Partnering and licensing

Partnering opportunities

Alliance and Partner Management Excellence

Products and Services

Prescription drugs and self-care products

Veterinary medicine

Active Pharmaceutical Ingredients

Contract manufacturing

Investors

Orion as an investment

Business environment

Market reviews

Market reviews 2017

Market reviews 2016

Market reviews 2015

Market reviews 2014

Market reviews 2013

Market reviews 2012

Market reviews 2011

Market reviews 2010

Market reviews 2009

Market reviews 2008

Market reviews 2007

CEO's review

CEO Timo Lappalainen's reviews 2017

CEO Timo Lappalainen's reviews 2016

CEO Timo Lappalainen's reviews 2015

CEO Timo Lappalainen's reviews 2014

CEO Timo Lappalainen’s reviews 2013

CEO Timo Lappalainen’s reviews 2012

CEO Timo Lappalainen's reviews 2011

CEO Timo Lappalainen's reviews 2010

CEO Timo Lappalainen’s reviews 2009

CEO Timo Lappalainen’s reviews 2008

CEO's reviews 2007

Financial Information

Key figures

Quarterly figures

Credit programmes

Outlook for 2018

Outlook for 2017

Outlook for 2016

Outlook for 2015

Outlook for 2014

Outlook for 2013

Outlook for 2012

Outlook for 2011

Outlook for 2010

Outlook for 2009

Outlook for 2008

Outlook for 2007

Outlook for 2006

Basis for outlook

Accounting policies

Calculation of key figures

Financial reviews and presentations

Other events

Capital Markets Days

Annual Reports

Share information

Share capital and shares

Share-related key figures

Treasury shares

Share price

Alternative exchanges monitor

Historical share prices

Total return calculator

Dividends

Analysts

Consensus estimates

Shareholders

Major shareholders by shares

Major shareholders by votes

Ownership structure

Flagging notifications

Insider register

Conversion of shares

Changes in shareholder's contacts

Transactions of managers

Messages to shareholders

Annual General Meetings

AGM 2018

AGM 2017

AGM 2016

AGM 2015

AGM 2014

AGM 2013

AGM 2012

AGM 2011

AGM 2010

AGM 2009

AGM 2008

AGM 2007

IR Calendar

Silent period

Archive

Investor Relations

News

Stock Exchange Releases

Press Releases

Managers' transactions

Subscribe to releases

Material Bank

Disclosure Policy

News archive

2017

2016

2015

2014

Corporate Governance

Corporate Governance

Corporate Governance Statement

AGM

Board of Directors

Activities and duties

Principles Concerning Diversity of the Board of Directors

Board members

Heikki Westerlund

Timo Maasilta

Sirpa Jalkanen

Ari Lehtoranta

Hilpi Rautelin

Eija Ronkainen

Mikael Silvennoinen

Board Committees

Nomination Committee

Authorisations of the Board of Directors

CEO and Executive Management Board

Activities and duties

Introductions of the Executive Management Board members

Timo Lappalainen

Satu Ahomäki

Markku Huhta-Koivisto

Olli Huotari

Liisa Hurme

Jari Karlson

Virve Laitinen

Christer Nordstedt

Employee representative Jani Korhonen

Remuneration

Share-based incentive plans

Risks and internal control

Strategic risks

Operational risks

Financial risks

Insider administration

Audit

Articles of Association

Slavery and Human Trafficking Statement

Sustainability

Policies

Our approach to corporate responsibility

Code of Conduct

Human Resources Policy

EHS Policy

Quality Policy

Anti-Corruption Policy

Supplier requirements

Pharmaceutical R&D Ethics Policy

Bioethics and Animal Welfare

Using Human Tissues, GMO and Stem Cells

Ethics in the Clinical Research Phases

Ethics in the Marketing Phase

Management Approaches of responsibility

Management of Product Responsibility

Management of Environmental Responsibility

Labour Practices and Decent Work

Management of Economic Responsibility

Human Rights Management

Management of Societal Relations

Sustainability Reports

Sustainability Report 2017

Management statement

Our efforts in the fight against antimicrobial resistance

Sustainable pharmaceutical product lifecycle management

Previous reports

Patient organisation collaboration

Stories about responsibility

Contact us

Invoicing addresses

Locations and contact persons

Sites and offices

Pharmaceutical manufacturing

Sales offices and representative offices

Animal Health

Fermion

Contact persons

Drug safety and product information

Research Research

Orion R&D

Orion's R&D Pipeline

Research areas

Oriontation — 100 ideas

Drug development

Scientific publications

Orion Research Foundation's grants

Careers at Orion Careers at Orion

Open Vacancies

Applying for a job – questions and answers

Working in the pharmaceutical industry

Developing competence at Orion

Building personnel well-being

Career stories

Students

Health Professionals

Employee representative Jani Korhonen

Specialist, Analytics Outsourcing

Jani Korhonen is the employee representative in the Executive Management Board.

Orion's century

1910s

A superstar of Finnish chemistry

It all began with Albin and woodfern

Orion’s milestones in the 1910s

1920s

A tireless promoter of children’s health

One big family

Orion’s milestones in the 1920s

1930s

Finnishness as an advertising asset

PR in the 1930s: Welcome to the Vallila plant!

Orion’s milestones in the 1930s

1940s

A miracle drug amidst the war

Orion relocated

Orion’s milestones in the 1940s

1950s

A legendary school for laboratory assistants

Finns’ favourite ointments

Orion’s milestones in the 1950s

1960s

The man behind the research

An idyllic estate

Orion’s milestones in the 1960s

1970s

How can I help you?

International horizons: rapid tests and Finnishness

Orion’s milestones in the 1970s

1980s

New address: Orionintie 1

“For manly pain” – from drugs to brands

Orion’s milestones in the 1980s

1990s

Joining forces with a competitor

An inhaler that helps asthmatics and the atmosphere

Orion’s milestones in the 1990s

2000s

The long road to market

The last hope for a heart patient

Orion’s milestones in the 2000s

2010s

Pink light to promote girls’ rights

From a mobile phone factory to a pharmaceutical plant

Orion’s milestone in the 2010s

About Orion

Management

Board of Directors

Executive management board

Orion values

Mission and strategy

Partnering and licensing

Partnering opportunities

Alliance and Partner Management Excellence

Products and Services

Prescription drugs and self-care products

Veterinary medicine

Active Pharmaceutical Ingredients

Contract manufacturing

Investors

Orion as an investment

Business environment

Market reviews

Market reviews 2017

Market reviews 2016

Market reviews 2015

Market reviews 2014

Market reviews 2013

Market reviews 2012

Market reviews 2011

Market reviews 2010

Market reviews 2009

Market reviews 2008

Market reviews 2007

CEO's review

CEO Timo Lappalainen's reviews 2017

CEO Timo Lappalainen's reviews 2016

CEO Timo Lappalainen's reviews 2015

CEO Timo Lappalainen's reviews 2014

CEO Timo Lappalainen’s reviews 2013

CEO Timo Lappalainen’s reviews 2012

CEO Timo Lappalainen's reviews 2011

CEO Timo Lappalainen's reviews 2010

CEO Timo Lappalainen’s reviews 2009

CEO Timo Lappalainen’s reviews 2008

CEO's reviews 2007

Financial Information

Key figures

Quarterly figures

Credit programmes

Outlook for 2018

Outlook for 2017

Outlook for 2016

Outlook for 2015

Outlook for 2014

Outlook for 2013

Outlook for 2012

Outlook for 2011

Outlook for 2010

Outlook for 2009

Outlook for 2008

Outlook for 2007

Outlook for 2006

Basis for outlook

Accounting policies

Calculation of key figures

Financial reviews and presentations

Other events

Capital Markets Days

Annual Reports

Share information

Share capital and shares

Share-related key figures

Treasury shares

Share price

Alternative exchanges monitor

Historical share prices

Total return calculator

Dividends

Analysts

Consensus estimates

Shareholders

Major shareholders by shares

Major shareholders by votes

Ownership structure

Flagging notifications

Insider register

Conversion of shares

Changes in shareholder's contacts

Transactions of managers

Messages to shareholders

Annual General Meetings

AGM 2018

AGM 2017

AGM 2016

AGM 2015

AGM 2014

AGM 2013

AGM 2012

AGM 2011

AGM 2010

AGM 2009

AGM 2008

AGM 2007

IR Calendar

Silent period

Archive

Investor Relations

News

Stock Exchange Releases

Press Releases

Managers' transactions

Subscribe to releases

Material Bank

Disclosure Policy

News archive

2017

2016

2015

2014

Corporate Governance

Corporate Governance

Corporate Governance Statement

AGM

Board of Directors

Activities and duties

Principles Concerning Diversity of the Board of Directors

Board members

Heikki Westerlund

Timo Maasilta

Sirpa Jalkanen

Ari Lehtoranta

Hilpi Rautelin

Eija Ronkainen

Mikael Silvennoinen

Board Committees

Nomination Committee

Authorisations of the Board of Directors

CEO and Executive Management Board

Activities and duties

Introductions of the Executive Management Board members

Timo Lappalainen

Satu Ahomäki

Markku Huhta-Koivisto

Olli Huotari

Liisa Hurme

Jari Karlson

Virve Laitinen

Christer Nordstedt

Employee representative Jani Korhonen

Remuneration

Share-based incentive plans

Risks and internal control

Strategic risks

Operational risks

Financial risks

Insider administration

Audit

Articles of Association

Slavery and Human Trafficking Statement

Sustainability

Policies

Our approach to corporate responsibility

Code of Conduct

Human Resources Policy

EHS Policy

Quality Policy

Anti-Corruption Policy

Supplier requirements

Pharmaceutical R&D Ethics Policy

Bioethics and Animal Welfare

Using Human Tissues, GMO and Stem Cells

Ethics in the Clinical Research Phases

Ethics in the Marketing Phase

Management Approaches of responsibility

Management of Product Responsibility

Management of Environmental Responsibility

Labour Practices and Decent Work

Management of Economic Responsibility

Human Rights Management

Management of Societal Relations

Sustainability Reports

Sustainability Report 2017

Management statement

Our efforts in the fight against antimicrobial resistance

Sustainable pharmaceutical product lifecycle management

Previous reports

Patient organisation collaboration

Stories about responsibility

Contact us

Invoicing addresses

Locations and contact persons

Sites and offices

Pharmaceutical manufacturing

Sales offices and representative offices

Animal Health

Fermion

Contact persons

Drug safety and product information

Introductions of the Executive Management Board members

Change country suomeksi

Building well-being

Asthma
Alzheimer's disease
Parkinson's disease
Breast cancer
Prostate cancer

Other channels

Facebook
Twitter
Twitter (IR)
Youtube

Orion Group

About Orion
Products and services
Partnering and licensing
Investors
Media
Sustainability
Corporate Governance
Health professionals

Research

Orion R&D
Research areas
R&D pipeline
Scientific publications

Careers at Orion

Open vacancies
Working at Orion
Students
Career stories

Other websites

fermion
Orion in other countries

Contact us
Privacy
Cookie Policy
About this website

Orion Corporation, Orionintie 1A, 02200 Espoo, PO Box 65, FI-02101 Espoo, Finland. Phone +358 10 4261 © Copyright Orion Corporation. Company code, VAT 19992126.